Search Results
May 17, 2026, 20:03 ET Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate
homeostasis. Extensive preclinical and clinical studies have demonstrated that combining receptor-blocking antibodies targeting ACVR2A/2B with GLP-1-based weight loss therapies can further reduce body fat while effectively mitigating lean mass loss. LET003 is the first ACVR2A/2B dual-target blocking
More news about: Harbour BioMed
May 15, 2026, 10:00 ET La energía limpia es clave para reducir el coste de utilizar combustibles fósiles
dólares anuales.Electrificar la calefacción y la cocina. Las bombas de calor y la cocina eléctrica pueden reducir la dependencia del gas y el GLP, a la vez que mejoran la asequibilidad para los hogares.Ampliar el uso de combustibles y fertilizantes ecológicos. Una producción de fertilizantes
More news about: Energy Transitions Commission
May 14, 2026, 16:40 ET Atrium Therapeutics Reports First Quarter 2026 Financial Results
to low double-digits on net sales.Progressed ATR 1072 program toward the clinic. Atrium has conducted the Good Laboratory Practice (GLP) toxicology studies required for the submission of an Investigational New Drug (IND) application for ATR 1072, a potential treatment designed to address
More news about: Atrium Therapeutics
May 14, 2026, 16:05 ET MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia Inc.
May 14, 2026, 10:31 ET Professional Hair Care Market to Reach USD 57.5 billion by 2033, Growing at a CAGR of 5.3% -- Allied Market Research
as a non-negotiable core value.The GLP-1 drug revolution's downstream effects on professional hair care deserve specific attention: emerging clinical evidence suggests that significant, rapid weight loss as induced by GLP-1 receptor agonists may accelerate telogen effluvium
More news about: Allied Market Research
May 14, 2026, 08:23 ET Americans Are Ready To Stop 'Maxxing' and Start Enjoying Food Again - And This Queso Brand Is Listening
foods, enjoy your life, and don't overthink it."The Data Supports the Max BurnoutAccording to the survey data, GLP-1s (57%), calorie counting (54%) and health tech data analysis (43%) are the topics leading the wellness space, with proteinmaxxing (28%), air frying
More news about: Pancho's Cheese Dip
May 14, 2026, 06:00 ET Lifeway Foods® Announces Record-Breaking Results for the First Quarter Ended March 31, 2026
functional product offerings. The consumer focus on health and wellness continues to increase, gut-health awareness is spreading and demand from GLP-1 users seeking nutrient-dense, probiotic foods is particularly strong. We address each of these trends with our flagship Lifeway Kefir and high-protein
More news about: Lifeway Foods, Inc.
May 13, 2026, 15:35 ET Frost & Sullivan Explores the Rise of the "Healthspan Economy" and Emerging Growth Opportunities in Nutraceuticals
optimisation. The report notes that GLP-1-driven innovation is reshaping both the pharmaceutical and nutraceutical industries, creating new opportunities for solutions focused on appetite control, satiety, energy regulation, and sustainable long-term wellness."As GLP-1 pathways gain traction, weight
More news about: Frost & Sullivan
May 13, 2026, 15:35 ET Frost & Sullivan Explores the Rise of the "Healthspan Economy" and Emerging Growth Opportunities in Nutraceuticals
optimisation. The report notes that GLP-1-driven innovation is reshaping both the pharmaceutical and nutraceutical industries, creating new opportunities for solutions focused on appetite control, satiety, energy regulation, and sustainable long-term wellness."As GLP-1 pathways gain traction, weight
More news about: Frost & Sullivan
May 13, 2026, 09:00 ET 9amHealth Raises $26M to Expand Into Chronic Conditions Driving the Majority of Employer Pharmacy Spend
protocols, labs, medication management, and continuous care, the company has delivered significant pharmacy cost savings amid rising demand for GLP-1 therapies while improving engagement and clinical outcomes.Building on this foundation, 9amHealth has already developed the clinical infrastructure,
More news about: 9amHealth
May 13, 2026, 08:00 ET MinuteClinic highlights access and outcomes in clinically supervised weight-loss program
Minuteclinic.com.1 MinuteClinic does not prescribe GLP-1s in Massachusetts or Missouri. Insurance coverage for GLP-1s varies by insurer, and we encourage patients to contact their insurance company to confirm costs.2
More news about: CVS Health
May 13, 2026, 07:00 ET SUANNUTRA USA Seals US Distribution Rights for TetraSOD®
all-encompassing and already feature in a full spectrum of supplement formulations targeting healthy ageing, sports and active nutrition, GLP-1 support, and cellular health," adds Gutiérrez Montero.A central mechanism of TetraSOD®'s action, highlighted in multiple preclinical
More news about: SuanNutra USA
May 13, 2026, 00:01 ET Beauty's Next Wave Sees Consumers Adding Aesthetic Procedures and Longevity Treatments to Regular Routines
beauty categories, with 70% investing more in premium or medical-grade skin care, and 50% adding more steps or ingredients to their routines.GLP-1s are also creating new beauty needs. Approximately 30% of optimizers report using them in the past 12 months. Of those who reported changes in facial
More news about: Boston Consulting Group (BCG)
May 12, 2026, 23:47 ET New Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function
A major new clinical study, SUPER 2, has been published in Nature Communications, reporting that Efsubaglutide Alfa, a long-acting GLP-1 receptor agonist, significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metformin, while also demonstrating
More news about: Innogen Pharmaceuticals
May 12, 2026, 20:00 ET Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions
highlight its differentiated profile as a GCG/GLP‑1 dual receptor agonist in terms of weight loss, glycemic control and metabolic benefits. In addition, the data on IBI3032(oral daily GLP-1 small molecule), IBI3042(oral weekly GLP-1 small molecule), IBI3040(amylin) and IBI3046(INHBE
More news about: Innovent Biologics
May 12, 2026, 18:01 ET Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Zepbound is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human
More news about: Eli Lilly and Company
May 12, 2026, 10:30 ET The $59B Quiet Shift Reshaping How Patients Access Care
collaboration with Novo Nordisk to make a broad assortment of FDA-approved GLP-1 medications available to eligible customers, including Wegovy, the only FDA-approved GLP-1 weight loss pill. The expansion positions Hims & Hers Health as the largest global
More news about: Equity Insider
May 12, 2026, 10:01 ET Life Science IT Market to Reach $62.5 billion, Globally, by 2033 at 11% CAGR: Allied Market Research
platforms that enable real-time sample tracking, automated workflows, and seamless integration with ERP. These tools are the basic building blocks of GMP/GLP compliant pharmaceutical manufacturing and R&D. Regulatory Technology (RegTech) Expansion: Increasing complexity in global drug approval
More news about: Allied Market Research
May 12, 2026, 08:00 ET NCPDP Highlights Innovation and Real-Time Progress at 2026 Annual Conference
MBA, Director of Payment Reconciliation for Medicare Part D, CMS discussed efforts to improve affordability and access through initiatives like the GLP bridge program, designed to help bring more predictable and affordable drug pricing to Medicare Part D beneficiaries. She also highlighted ongoing work
More news about: NCPDP
May 12, 2026, 07:05 ET Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the treatment of metabolic disorders, including obesity. The compound is being evaluated in both oral and subcutaneous formulations.About GLP-1 and Dual GLP-1/GIP
More news about: Viking Therapeutics, Inc.
May 12, 2026, 02:08 ET GIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical's Phase III Results Signal Differentiation in Weight Loss Arena
combined with GLP-1. Multiple reviews have identified GIP as a key regulatory hormone in the gut–bone axis, mediating both bone resorption inhibition and bone formation modulation during postprandial bone remodeling.Along the traditional single-target GLP-1 pathway, rapid
More news about: BrightGene
May 11, 2026, 14:12 ET Weight Management Market to Reach USD 381.5 Billion, Globally, by 2033 at 10.3% CAGR: Allied Market Research
weight management market report, several high-impact forces shape direction growth during 2023-2033 are: The GLP-1 Drug Revolution Mass uptake of GLP-1 receptor agonist drugs such as Wegovy and Ozempic has challenged conventional approaches to weight management. As FDA approval
More news about: Allied Market Research
May 11, 2026, 08:31 ET MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
(OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR),
More news about: MetaVia Inc.
May 09, 2026, 11:00 ET PureHealth Research Announces Berberine-Infused Natural GLP-1 Supplements to Support the Body's Native Metabolic Function
SolutionThe GLP-1 hormone plays a pivotal role in regulating appetite and metabolic pace, signaling fullness after meals and supporting healthy glucose uptake. However, modern dietary patterns, chronic stress, and the natural aging process can collectively impair GLP-1 efficiency –
More news about: PureHealth Research LLC
May 08, 2026, 06:02 ET 10 Top Press Releases from April
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictionsWhen used alongside a reduced-calorie
More news about: PR Newswire